Dr. Wagner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-5204Fax+1 617-632-3408
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2005- Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1997
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 1999 - 2026- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors Start of enrollment: 2007 Aug 01
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Start of enrollment: 2010 Sep 01
- Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia Start of enrollment: 2014 Dec 01
Publications & Presentations
PubMed
- 457 citationsMyc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.Andrew J. Wagner, John M. Kokontis, Nissim Hay
Genes & Development. 1994-12-01 - 189 citationsEffect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical TrialWilliam D. Tap, Andrew J. Wagner, Patrick Schöffski, Javier Martin-Broto, Anders Krarup-Hansen
JAMA. 2020-04-07 - 235 citationsMulticenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor SarcomasSuzanne George, Priscilla Merriam, Robert G. Maki, Annick D. Van den Abbeele, Jeffrey T. Yap
Journal of Clinical Oncology. 2009-07-01
Lectures
- ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open l...2019 ASCO Annual Meeting - 6/1/2019
- Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su)...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
A Rare Occurrence of BHD and PEComa – Perspectives from a Patient and a DoctorMarch 18th, 2022
Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComaNovember 14th, 2019
Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComaJune 4th, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
